A Phase II Study of a Three-Drug Combination (Cisplatin, Ifosfamide and Vinorelbine) plus Granulocyte-Colony Stimulating Factor in Advanced Non Small Cell Lung Cancer
Authors: Tognoni, A.; Cadenotti, L.; Pensa, F.; Vaira, F.; Vigani, A.; Bancalari, L.; Cordani, S.; Maggiani, R.; Canessa, P.A.; Pronzato, P.
Source: Journal of Chemotherapy, Volume 11, Number 4, 1999 , pp. 306-309(4)
Publisher: Maney Publishing
Abstract:Twenty-nine patients with advanced non-small-cell lung cancer (NSCLC) were treated with a combination of cisplatin 20 mg/m2 days 1-3, ifosfamide 1500 mg/m2 days 1-2 (plus mesna as uroprotector) and vinorelbine 25 mg/m2 days 1 and 5; filgrastim was given at the dose of 300 μg subcutaneously from day 8 to day 15. A response rate of 28% was observed. The activity of this combination in an outpatient setting, with acceptable toxicity, has been demonstrated.
Document Type: Research Article
Publication date: 1999-01-01